Olema Pharmaceuticals (OLMA) Interest Expenses (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Interest Expenses of $91.9 million for Q1 2026, up 6861.44% year-over-year from $1.3 million in Q1 2025, and up 30327.48% quarter-over-quarter from $302000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Interest Expenses (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Interest Expenses for 7 consecutive years, with $91.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 6861.44% year-over-year to $91.9 million; the TTM figure through Mar 2026 stood at $91.9 million (up 6861.44% YoY), while the FY2025 annual figure was $235.7 million, up 3034.19% from the prior year.
- Interest Expenses climbed to $91.9 million in Q1 2026 per OLMA's latest filing, from $302000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $91.9 million in Q1 2026 and bottomed at $263000.0 in Q4 2023.
- Historically, Interest Expenses has averaged $18.6 million across 5 years, with a median of $3.2 million in 2022.
- Annual changes were most pronounced in 2025 — Interest Expenses sank 99.29% — and 2026, when it soared 6861.44%.
- Olema Pharmaceuticals' Interest Expenses stood at $323000.0 in 2022, then fell by 18.58% to $263000.0 in 2023, then advanced by 16.35% to $306000.0 in 2024, then retreated by 1.31% to $302000.0 in 2025, then soared by 30327.48% to $91.9 million in 2026.
- Business Quant data shows OLMA's Interest Expenses at $91.9 million in Q1 2026, $302000.0 in Q4 2025, and $312000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 68.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.68 Mn |
| Jun 30, 2026 | 68.68 Mn |
| Mar 31, 2026 | 91.89 Mn |
| Mar 31, 2026 | 91.89 Mn |
| Dec 31, 2025 | 302,000.00 |
| Dec 31, 2025 | 302,000.00 |
| Sep 30, 2025 | 312,000.00 |
| Sep 30, 2025 | 312,000.00 |
| Jun 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.93 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 306,000.00 |
| Dec 31, 2024 | 306,000.00 |
| Sep 30, 2024 | 44.24 Mn |
| Sep 30, 2024 | 44.24 Mn |
| Jun 30, 2024 | 37.10 Mn |
| Jun 30, 2024 | 37.10 Mn |
| Mar 31, 2024 | 40.73 Mn |
| Mar 31, 2024 | 40.73 Mn |